Optimising Immunotherapy for Maori with Advanced Non Small Cell Lung Cancer

Optimising Immunotherapy Outcomes for Maori with Advanced Non Small Cell Lung Cancer: A Mixed-Methods Study Assessing Clinical Profiles, PDL1 Testing, and Survival

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12624001466538

Acronym

Optimise

Enrollment

Registered

2024-12-17

Start date

2025-02-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Lung cancer is the leading cause of cancer death in New Zealand, with Maori suffering the highest incidence and death rate. Immunotherapy significantly improves survival in advanced lung cancer and was funded to treat New Zealanders in April 2023. PDL1 is a test on cancer tissue that can predict how well immunotherapy works. This mixed-methods observational study will meet three objectives: 1. Describe the experience of Maori receiving immunotherapy for NSCLC in the New Zealand public health system. 2. Map the clinical and PDL1 profile in Maori with advanced NSCLC referred to receive immunotherapy. 3: Measure survival for Maori receiving first-line immunotherapy for advanced NSCLC. This new biomedical, clinical and health system-level knowledge will optimise the benefits of immunotherapy for Maori with advanced lung cancer to reduce further inequities.

Interventions

Participants will be asked to complete: -Hua Oranga questionnaires (takes about 5 minutes to complete) - before starting immunotherapy, 3 months after commencing immunotherapy and 6 months after commencing immunotherapy -EORTC-QLQC30 (takes about 10 minutes to complete) - before cycle 1, before cycle 2, before cycle 3, and 9 weekly until 12 months or immunotherapy discontinuation -EORTC-QLQ-LC13 (takes about 10 minutes to complete) - before cycle 1, before cycle 2, before cycle 3, and 9 weekly until 12 months or immunotherapy discontinuation. Participants will be asked to report immunotherapy related adverse events from time of starting immunotherapy for 12 months or immunotherapy discontinuation. The overall duration of observation is from the time of starting immunotherapy for 12 months or until immunotherapy discontinuation.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1 Self-identified Maori Patients with a diagnosis of advanced Lung Cancer (NSCLC) 2 Prescribed first-line palliative pembrolizumab immunotherapy with or without concurrent chemotherapy 3 Aged greater than or equal to 18 years at time of signing informed consent form

Exclusion criteria

1 Patients receiving treatment outside of the Northern Region of New Zealand

Outcome results